Placebo:Placebo treatment

5 trials

Sponsors

Beijing University of Chinese Medicine, 904th Hospital of Joint Logistic Support Force, Harbin Medical University

Conditions

Hyperlipidemia populationObesitymild hyperlipidemiamild hyperlipidemia combined with obesityspontaneous subarachnoid hemorrhage

Phase 1

Clinical study on anti-mild hyperlipidemia of Canna edulis RS3 resistant starch

Active, not recruitingChiCTR2200062871

Beijing University of Chinese Medicinemild hyperlipidemia

Start: 2022-09-01Updated: 2023-04-12

Clinical study of Canna edulis RS3 resistant starch resistant to mild hyperlipidemia clinical research

Active, not recruitingChiCTR2300069520

Beijing University of Chinese Medicinemild hyperlipidemia combined with obesity

Start: 2023-03-20Updated: 2023-05-29

Phase 4

Pioglitazone in spontaneous subarachnoid hemorrhage: A multicentre, double-blind, randomised trial

Active, not recruitingChiCTR2200062954

904th Hospital of Joint Logistic Support Forcespontaneous subarachnoid hemorrhage

Start: 2022-10-01Updated: 2023-04-12

Unknown Phase

Effects of histidine supplement on obese females: a randomized controlled trial

Active, not recruitingChiCTR-TRC-11001551

Harbin Medical UniversityObesity

Start: 2011-01-03Updated: 2017-04-18

Effects of mangiferin supplement on hyperlipidemia population: a randomized controlled trial

Active, not recruitingChiCTR-TRC-13003962

Harbin Medical UniversityHyperlipidemia population

Start: 2013-12-10Updated: 2017-04-18

Related Papers

Type 3 resistant starch from Canna edulis reduce lipid levels in patients with mild hyperlipidemia through altering gut microbiome: A double- blind randomized controlled trial

Pharmacological Research2024-06-0116 citations

Pioglitazone in spontaneous subarachnoid hemorrhage: study protocol of a multicenter, double-blind, randomized trial (PSSH)

Frontiers in Pharmacology2024-01-05